ReviewCurrent hematologic malignancy reports2019
The Clinical Challenge of Idiopathic Cytopenias of Undetermined Significance (ICUS) and Clonal Cytopenias of Undetermined Significance (CCUS).
Review in Current hematologic malignancy reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Reconceptualizing Aplastic Anemia-Seed, Worm, Soil.Journal of clinical laboratory analysis · 2026Review
- Long-term outcomes of patients with refractory cytopenia of childhood under observation only.Blood advances · 2025Article
- Clonal hematopoiesis in myeloid malignancies and solid tumors.Nature cancer · 2025Review
- Review
- Rapid and sustained response to luspatercept and eltrombopag combined treatment in one case of clonal cytopenias of undetermined significance with prior failure to cyclosporin and androgen therapy: a case report.Therapeutic advances in hematology · 2024Article
- Article
- Utility of plasma cell-free DNA forHaematologica · 2022Article
- Morphologic, immunophenotypic, and molecular genetic comparison study in patients with clonal cytopenia of undetermined significance, myelodysplastic syndrome, and acute myeloid leukemia with myelodysplasia-related changes: A single institution experience.International journal of laboratory hematology · 2022Article
- Molecular Pathways in Clonal Hematopoiesis: From the Acquisition of Somatic Mutations to Transformation into Hematologic Neoplasm.Life (Basel, Switzerland) · 2022Review
- Clonal Hematopoiesis and Myeloid Neoplasms in the Context of Telomere Biology Disorders.Current hematologic malignancy reports · 2022Review
- Inflammatory Cytokine Profiles Do Not Differ Between Patients With Idiopathic Cytopenias of Undetermined Significance and Myelodysplastic Syndromes.HemaSphere · 2022Article
- Article
- Exploring the Associations Between Clonal Hematopoiesis of Indeterminate Potential, Myeloid Malignancy, and Atherosclerosis.Methods in molecular biology (Clifton, N.J.) · 2022Review
- The genetic analysis of Chinese patients with clonal cytopenias using targeted next-generation sequencing.Molecular cytogenetics · 2021Article
- Peripheral blood cytopenias in the aging general population and risk of incident hematological disease and mortality.Blood advances · 2021Article
- Pathologic Spectrum and Molecular Landscape of Myeloid Disorders Harboring SF3B1 Mutations.American journal of clinical pathology · 2021Article
- From Clonal Hematopoiesis to Therapy-Related Myeloid Neoplasms: The Silent Way of Cancer Progression.Biology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewTo review terminology, diagnostic algorithms, and clinical outcomes for patients with unexplained blood cytopenias. RECENT
findingsPatients with cytopenias that remain unexplained after organized diagnostic testing can be described as having "idiopathic cytopenias of undetermined significance" (ICUS). Patients with unexplained cytopenias have a risk of progression to clonal myeloid neoplasms, including myelodysplastic syndromes (MDS). If a somatic mutation in a gene associated with leukemia is detectable in hematopoietic tissue, especially if multiple mutations with a high (> 10%) variant allele frequency are present, the risk of progression to frank neoplasia is greater than if such mutations are not detected. These patients can be described with the term, "clonal cytopenias of undetermined significance" (CCUS). CCUS patients have a natural history similar to lower-risk MDS. For patients with unexplained cytopenias, longitudinal follow-up including serial monitoring of blood counts is appropriate in view of the progression risk. Genetic testing may aid in risk stratification.
Indexed as
Identifiers
31696381What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.